Economist: Pharmas Are Protected 'Fragile Little Birds'
This article was originally published in Scrip
Executive Summary
While makers of high-priced specialty drugs in the US like to think they are free-enterprisers operating in the competitive markets, what those firms really are, argued Princeton economics professor Uwe Reinhardt, are "fragile little birds" protected by the government, which he said "carefully shields" the companies from the "harsh vagaries of truly free, competitive markets."
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.